News

According to the report, Pfizer spent GBP3.88 billion for R&D in 2006 while Johnson & Johnson (J&J) invested GBP3.64 billion in research. While Pfizer pushed itself to the

The Phase III study, known as Defend, will be conducted at multiple centers in North America and Europe and will evaluate whether a single course of otelixizumab reduces

Under the terms of the agreement, Grunenthal will supply Obecure with betahistine and matching placebo tablets for use in its upcoming clinical studies. Pending successful development and receipt

In this study, the drug significantly reduced itch symptoms in patients with chronic idiopathic urticaria (CIU), or hives of unknown cause that last for a period of at

Under the terms of the merger agreement, EP MedSystems shareholders will receive $3 of consideration for each EP MedSystems share they own, with the option of receiving that

The net proceeds from this offering will be used for clinical development of existing product candidates and other general corporate purposes. The closing of the transaction is expected

CMC Icos will be responsible for process development, manufacturing scale-up and current good manufacturing practices (cGMP) manufacturing of GGF2. Acorda plans to use the supply of GGF2 produced

This randomized, dual-arm Phase II study will evaluate IMC-A12 as a single agent and in combination with Erbitux (cetuximab) in patients with metastatic head and neck cancer who

The trial is a multi-center, multi-national, randomized, double-blind, placebo-controlled study. The primary objective of the study is to assess the safety and tolerability of aerosolized ALN-RSV01 versus placebo